After a failed discectomy and a recommendation for multi-level spinal fusion, many patients with chronic discogenic pain feel out of options. Intra-annular fibrin injection — a minimally invasive biologic disc repair procedure — may help seal annular tears and reduce pain in select patients. Candidacy is evaluated individually, and outcomes vary; some patients report meaningful functional recovery.

Patient Overview

A 52-year-old former construction foreman presented to our clinical team with a complex history of chronic low back pain. More than 25 years of heavy lifting, repetitive bending, and prolonged standing had placed sustained mechanical stress on his lumbar spine. Despite an otherwise generally healthy lifestyle, his pain had severely curtailed physical activity for years.

His primary complaint was severe, constant low back pain — rated 7–8 out of 10 — that frequently radiated into his buttocks and thighs. Sitting, standing, bending, and lifting all exacerbated symptoms. He reported waking multiple times nightly, persistent fatigue, and a marked decline in his ability to engage with family. His medical history was notable for well-controlled hypertension and no other major systemic conditions.

The Challenge

Chronic back pain had reshaped every part of this patient’s life. He had already left a career he valued because the physical demands became impossible to manage. That transition brought financial strain and a loss of purpose that compounded his physical symptoms. Sitting beyond 15–20 minutes was unbearable; standing for similar periods intensified his pain. Activities he once took for granted — gardening, fishing, time with grandchildren — were no longer accessible.

MRI imaging revealed significant multi-level degenerative disc disease at L3–L4, L4–L5, and L5–S1, with disc height loss, desiccation, and multiple annular tears. The L5–S1 level showed the most pronounced changes, where a prior herniation had been surgically addressed. Those tears — structural damage to the outer annulus fibrosus — were identified as a primary driver of his persistent discogenic pain, a condition in which the disc itself generates pain signals through structural breakdown rather than nerve compression alone.

His situation was further complicated by the prior discectomy, which had not provided lasting relief, and by continued degeneration at adjacent levels. Several spine specialists had reviewed his case and concluded that multi-level lumbar fusion at L3–L4, L4–L5, and L5–S1 was the only remaining surgical option. That recommendation — irreversible and involving substantial recovery — was something he wanted to avoid if any viable alternative existed.

Previous Treatments Tried

Before arriving at our clinic, this patient had worked through an extensive course of conventional treatments, each providing temporary benefit at best:

• Epidural Steroid Injections (ESIs): More than six injections over several years initially provided mild, short-term relief. Over time the benefit diminished entirely, suggesting symptom suppression rather than structural correction.
• Physical Therapy: Multiple rounds improved muscle conditioning and posture, but the underlying disc pain persisted. Symptoms returned with any increase in activity level.
• Chiropractic Care: Adjustments offered transient relief from muscle stiffness but did not meaningfully address chronic discogenic pain.
• Oral Medications: NSAIDs, muscle relaxants, and brief opioid courses provided partial symptom management with side effects and no structural benefit.
• L5–S1 Microdiscectomy: Performed approximately five years prior, the procedure initially resolved radiculopathy. Within two years, his original low back pain returned, accompanied by new symptoms consistent with recurrent disc pathology or adjacent segment degeneration — a recognized complication following discectomy.

With conservative options exhausted and multi-level fusion on the table, this patient sought a biologic approach to disc repair rather than an irreversible structural change. Patients in this situation are evaluated on an individual basis; not every failed discectomy patient qualifies for fibrin disc treatment, and candidacy depends on specific imaging and clinical findings.

Our Approach

Our clinical team conducted a comprehensive evaluation, including a detailed review of medical history, physical examination, and advanced imaging. MRI findings confirmed distinct annular tears at L3–L4, L4–L5, and L5–S1, correlating with his reported pain pattern. After reviewing his history of failed conservative care and prior surgery, our team determined he met the candidacy criteria for intra-annular fibrin injection.

This biologic disc repair technique delivers a fibrin solution directly into damaged annular tissue with the goal of sealing tears, reducing inflammatory chemical leakage from the nucleus, and supporting structural repair from within. Compared to the proposed fusion surgery, this approach offered several meaningful differences:

• Minimally invasive: Thin needle insertion rather than open incisions reduces tissue disruption and may shorten recovery in appropriate candidates.
• Motion preservation: Unlike fusion, which permanently immobilizes treated segments, fibrin disc treatment aims to maintain natural spinal movement.
• Biologic mechanism: Fibrin is a natural protein central to wound healing. Delivering it directly to the annular tear site targets the structural source of discogenic pain in ways symptom management alone cannot.
• Avoidance of fusion-associated risks: Multi-level fusion carries risks including infection, hardware complications, prolonged hospitalization, and adjacent segment disease. This patient was already experiencing adjacent segment effects from his prior discectomy.

Before proceeding, our team discussed realistic expectations with this patient in detail. Biologic healing is gradual, outcomes vary by case, and no procedure carries a guarantee of full relief. He understood this represented a different model of care and agreed to the treatment protocol.

Treatment Process

The intra-annular fibrin injection was performed following standard clinical safety protocols. Pre-procedural planning included a review of his most recent MRI to map the precise location and character of each annular tear.

On the day of the procedure, local anesthesia was administered to the skin and superficial tissues. Under continuous fluoroscopic (real-time X-ray) guidance, a thin specialized needle was advanced to each affected disc level — L3–L4, L4–L5, and L5–S1. Fluoroscopic imaging is essential for accuracy and to protect surrounding structures throughout the procedure.

Once needle placement was confirmed within each annular tear, the fibrin biologic solution was injected. Fibrin infiltrates the torn annulus, creating a biologic seal intended to prevent further leakage of inflammatory nucleus material and support repair of the outer disc wall over time.

The procedure was completed in approximately 60–90 minutes, with the patient awake and communicative throughout. A short monitoring period followed before discharge. Post-procedure instructions emphasized rest, avoidance of strenuous activity, and a gradual return to gentle movement. Mild, transient post-procedural soreness is common and was managed with standard over-the-counter options.

A structured rehabilitation program emphasizing core stability and posture began after the initial healing phase. Regular follow-up appointments allowed the team to monitor progress and adjust the recovery plan as needed.

Recovery and Outcomes

This patient’s recovery unfolded gradually over twelve months. His experience reflects one individual’s response to treatment and is not predictive of outcomes for other patients. Recovery timelines and functional gains vary significantly by case.

• Weeks 1–2: Mild post-procedural soreness managed with over-the-counter pain relief. Expected during the early healing phase.
• Months 2–3: The patient reported a steady reduction in baseline pain. The sharp, burning quality that had persisted for years began to lessen. Average pain dropped to the 4–5 range and sleep quality improved.
• Months 4–6: Continued improvement. Average pain fell further, with most days in the 2–3 range. He could sit for up to 45 minutes without significant discomfort and stand for approximately an hour. Light walking and gentle stretching were tolerable. Radiating pain into the buttocks and thighs had largely resolved.
• Months 9–12: At the twelve-month mark, the patient reported a substantial change in daily function. Pain on most days registered in the 1–2 range. He resumed multi-mile walks, extended time with grandchildren, and volunteering for light-duty community work. He was comfortable driving for over an hour. He was not entirely pain-free, but his functional capacity had improved well beyond his initial expectations.

Physical examination at follow-up showed increased range of motion and reduced tenderness at the treated spinal segments. Standardized functional capacity questionnaires reflected meaningful improvement in the ability to perform daily activities.

Expert Take

Patients who present with a prior failed discectomy and multi-level annular tears represent one of the more clinically challenging groups in spine care. When conservative measures have been exhausted and the remaining recommendation is multi-level fusion, some candidates may benefit from biologic disc repair as an intermediate option — provided they meet specific imaging and clinical criteria. Disc integrity, the correlation between pain pattern and structural findings, and the absence of instability requiring fusion are the key evaluation factors. Outcomes are individual; patient selection and adherence to the recovery protocol drive results as much as the procedure itself.

Key Takeaways

1. Annular tears are a primary pain source in many chronic back pain cases. When the annulus fibrosus is structurally compromised, the disc itself can generate persistent pain signals. Targeting the tear directly with biologic repair may provide relief that symptom management alone cannot sustain.
2. Fibrin disc treatment may offer an alternative to fusion for select candidates. Patients facing multi-level lumbar fusion after prior surgical failure may qualify for intra-annular fibrin injection. Each case is evaluated individually; the procedure is not appropriate for all presentations. Learn more about signs that suggest candidacy for non-surgical disc treatment.
3. Failed back surgery does not eliminate all pathways. A discectomy that provided only temporary relief does not necessarily mean biologic repair options are closed. Some patients with recurrent or adjacent-level disc pathology may still meet candidacy criteria. See related guidance on exploring regenerative disc repair before additional surgery.
4. Biologic healing requires time and protocol adherence. Results develop over months, not weeks. Patients who follow their post-treatment rehabilitation plan tend to achieve better functional outcomes, though individual variation is significant.
5. Functional restoration, not just pain scores, defines meaningful success. The ability to resume activities that matter — time with family, movement, a sense of purpose — reflects the broader goal of spine care. Pain reduction is one measure; quality of life is the more meaningful one.

“For years, I felt stuck in a nightmare of pain — especially after my first surgery didn’t hold up. Doctor after doctor told me fusion was my only choice, and I was terrified. The fibrin treatment gave me my life back without another major surgery. I can walk, spend time with my grandkids, and finally feel like myself again.”

— Construction Worker, ValorSpine Patient

If you’ve had a prior discectomy and are now facing a fusion recommendation, our clinical team evaluates each case individually. Explore five questions to ask before agreeing to spine surgery, review spinal fusion alternatives, or read additional case perspectives including a construction worker’s return to the job site with regenerative spine care and an adjacent segment disease fibrin case study.